Abstracts tagged "Rheumatoid Factor"

Abstract Number: 407 • 2014 ACR/ARHP Annual Meeting
Serum 14-3-3η Protein Supplements Traditional Rheumatoid Arthritis Biomarkers
Olga Zhukov¹, Jonnielyn Rivera¹, Charles M. Rowland², Joanna M. Popov¹ and Stanley J. Naides³, ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²Bioinformatics, Celera, Alameda, CA, ³Immunology, Quest Diagnostics, San Juan Capistrano, CA
Background/Purpose: The 14-3-3 family of chaperonin proteins consists of 7 isomers. The tissue distribution of the 14-3-3η (eta) isoform is limited to synovial tissue and…
Abstract Number: 362 • 2014 ACR/ARHP Annual Meeting
14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?
Dirkjan van Schaardenburg¹, Walter P. Maksymowych², Maarten Boers³, Samina Turk⁴, Mairead Murphy⁵ and Anthony Marotta⁶, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁴Reade, Amsterdam, Netherlands, ⁵Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁶1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose RF and ACPA are used for early diagnosis and in prediction models for the risk of RA development in arthralgia patients. There remains a…
Abstract Number: 360 • 2014 ACR/ARHP Annual Meeting
88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis
Gilles Boire¹, Nathalie Carrier², Artur Jose de Brum-Fernandes³, Patrick Liang⁴, Ariel Masetto⁵, Yuan Gui⁶, Mairead Murphy⁶, Walter P. Maksymowych⁷ and Anthony Marotta⁸, ¹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Rheumatology, Universite de Sherbrooke, Sherbrooke, QC, Canada, ³Department of Medicine, Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, CHUS, Sherbrooke, QC, Canada, ⁵Rheumatology, CHUS, Fleurimont, QC, Canada, ⁶Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁸1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose The 14-3-3η protein has been described as a mechanistic marker that is detectable in serum during the very early stages of RA development. A…
Abstract Number: 372 • 2014 ACR/ARHP Annual Meeting
Diagnostic Accuracy and Associated Costs of Rheumatoid Factor Testing in Primary Care: A Population-Based Cohort Study in Spain
Raashid Luqmani¹, Klara Morsley², Anne Miller³, Christopher J. Edwards⁴, M. Kassim Javaid⁵, Daniel Prieto-Alhambra⁶, Rafael Pinedo-Villanueva^7,8, Manuel Medina Peralta⁹, Sebastian Calero Munoz⁹, Nigel Arden^10,11, Francesc Fina-Aviles⁹ and Cyrus Cooper¹², ¹Oxford NIHR Musculoskeletal Biomedical Research Unit, Oxford, United Kingdom, ²Oxford University Hospitals NHS Trust, Nuffield Orthopaedic Centre, Oxford, United Kingdom, ³Rheumatology, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ⁴University Hospital Southampton, Southampton, United Kingdom, ⁵Rheumatology, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Oxford, United Kingdom, ⁶NIHR Musculoskeletal Biomedical Research Unit, Oxford, United Kingdom, ⁷NDORMS, University of Oxford, Oxford, United Kingdom, ⁸MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ⁹Institut Català de la Salut, Barcelona, Spain, ¹⁰NIHR Musculoskeletal Biomedical Research Unit University of Oxford, Oxford, United Kingdom, ¹¹University of Southampton, Southampton, United Kingdom, ¹²MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom
Background/Purpose: To assess the sensitivity, specificity, and predictive values of rheumatoid factor (RF) as a test for rheumatoid arthritis (RA) in primary care, and to…
Abstract Number: 1309 • 2013 ACR/ARHP Annual Meeting
Prognosis Of Seronegative Patients In a Large Prospective Cohort Of Patients With Early Inflammatory Arthritis
Lillian J. Barra¹, Janet E. Pope², Boulos Haraoui³, Carol A. Hitchon⁴, J. Carter Thorne⁵, Edward C. Keystone^6,7, Diane Tin⁸, Gilles Boire⁹ and Vivian P. Bykerk¹⁰, ¹Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ³Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁴Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Rheumatoid Factor (RF) and anti-Cyclic Citrullinated Peptide (anti-CCP) are believed to be associated with more severe clinical outcomes; however, studies in Early Inflammatory Arthritis…
Abstract Number: 1158 • 2013 ACR/ARHP Annual Meeting
Decreased NK-Cell Numbers and Upregulation Of Markers Of Systemic Inflammation In Autoantibody –Positive Arthralgia Patients and Early Rheumatoid Arthritis Patients But Not In Autoantibody-Negative Rheumatoid Arthritis Patients
Paulina Chalan¹, Johan Bijzet², Kornelis S.M. van der Geest¹, Bart-Jan Kroesen³, Annemieke M.H. Boots^4,5 and Elisabeth Brouwer¹, ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Dept. of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Groningen Research initiative on healthy Ageing and Immune Longevity (GRAIL), Groningen, Netherlands
Background/Purpose: Identification of seropositive individuals at risk for arthritis development would open opportunities for early clinical intervention. In a recent study on seropositive arthalgia patients…
Abstract Number: 870 • 2013 ACR/ARHP Annual Meeting
How To Predict That Early Arthritis Without Rheumatoid Factor and ACPA Becomes Rheumatoid Arthritis According To ACR/EULAR 2010 After a 3-Years Follow-Up? Results From The Espoir Cohort
Gaël Mouterde¹, Cédric Lukas², Nathalie Rincheval³, Alain Saraux⁴, Philippe Dieude⁵ and Bernard Combe⁶, ¹Rheumatology, Montpellier 1 University, Lapeyronie Hospital, Montpellier, France, ²Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ³Institut Universitaire de Recherche Clinique, Montpellier, France, ⁴Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France, ⁵Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, ⁶Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France
Background/Purpose: To describe disease course of patients without rheumatoid factor (RF) and anti-citrullinated protein auto-antibodies (ACPA) in an inception cohort of early arthritis patients. To determine…
Abstract Number: 423 • 2013 ACR/ARHP Annual Meeting
Serological Biomarkers For The Development Of Rheumatoid Arthritis Related Interstitial Lung Disease
Elena Nikiphorou¹, Esther Chan², Vadivelu Saravanan², Julie Dawson³, Navtej Sathi⁴, Felix Woodhead⁵, Mohamed Nisar⁶, Subhashini Arthanari⁶, Yasmeen Ahmad⁷, Adam Young⁸ and Clive Kelly², ¹Research Department of Epidemiology & Public Health, UCL and Rheumatology Department, St Albans City Hospital, ERAS, St Albans City Hospital & University College London (UCL), London, United Kingdom, ²Rheumatology, Queen Elizabeth Hospital, Gateshead, United Kingdom, ³Rheumatology, St Helens Hospital, St Helens, United Kingdom, ⁴Rheumatology, Wrightington Hospital, Wigan, United Kingdom, ⁵Respiratory, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, ⁶Rheumatology, Burton Hospital, Burton-on-Trent, United Kingdom, ⁷Department of Rheumatology, Peter Maddison Research Centre, Bangor, United Kingdom, ⁸Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose: Interstitial Lung Disease (ILD) is the commonest manifestation of lung disease in Rheumatoid Arthritis (RA) and the only complication reported to be increasing in…
Abstract Number: 183 • 2013 ACR/ARHP Annual Meeting
The Performance Of a Point Of Care Test For Detection Of Anti-Mutated Citrullinated Vimentin and Rheumatoid Factor In Early Rheumatoid Arthritis
Preeda Rojanasantikul¹, Prapa Pattrapornpisut², Kulvara Anuruckparadorn³ and Wanruchada Katchamart¹, ¹Division of Rheumatology, Department of Internal Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, ²Department of Internal Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ³Department of Transfusion Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
Background/Purpose: Besides rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (ACPA), a newer serologic marker, was added to the new American College of Rheumatology (ACR)/European League…
Abstract Number: 2394 • 2013 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis, Smoking Is Not Primarily Associated With Anti-Citrullinated Protein Antibodies, But With The Presence Of Multiple Autoantibodies
Ammar Muhammad¹, Tineke van Wesemael², Yuta Kochi³, Maria Mjaavatten⁴, Kirsten Wevers-de-Boer¹, Cornelia F. Allaart¹, Leendert A. Trouw¹, Akari Suzuki³, Kazuhiko Yamamoto⁵, Annette H.M. van der Helm-van Mil¹, Tom W.J. Huizinga¹, René E.M. Toes¹ and Diane van der Woude¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: Smoking is associated with the presence of several autoantibodies in various autoimmune diseases. In rheumatoid arthritis (RA), smoking has been described to be specifically…
Abstract Number: 2291 • 2013 ACR/ARHP Annual Meeting
Only Rheumatoid Factor-Positive Subset Of Anti-Citrullinated Peptide/Protein Antibody-Negative Rheumatoid Arthritis Seroconverts To Anti-Citrullinated Peptide/Protein Antibody-Positive
Ryosuke Hiwa¹, Koichiro Ohmura¹, Shuichiro Nakabo¹, Chikashi Terao², Ran Nakashima¹, Yoshitaka Imura³, Naoichiro Yukawa⁴, Hajime Yoshifuji¹, Motomu Hashimoto⁵, Moritoshi Furu⁶, Hiromu Ito⁶, Takao Fujii⁶ and Tsuneyo Mimori^1,6, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Center for Genomic Medicine, Kyoto University, Kyoto, Japan, ³Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁶Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: 216 (17.3%) out of 1,246 RA patients were negative for ACPA. In 149 cases of the ACPA-negative RA whose ACPA were measured more than…
Abstract Number: 2298 • 2013 ACR/ARHP Annual Meeting
Upper-Half Serum IgA (20+ TU/ml) and IgM (10+ IU/ml) Levels Significantly Predicted The Long-Term (mean 12 yrs) Onset Of Rheumatoid Arthritis When Combined, But Neither test Individually In Their Respective Full Ranges Of Values
Alfonse T. Masi¹, Azeem A. Rehman¹, Jean C. Aldag¹, Huaping Wang², Ned J. Goertzen³ and Marius C. Teodorescu⁴, ¹Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, ²Pediatrics, University of Illinois College of Medicine at Peoria, Peoria, IL, ³University of Illinois College of Medicine at Peoria, Peoria, IL, ⁴Microbiology, TheraTest Laboratories Inc, Lombard, IL
Background/Purpose: Serum rheumatoid factor (RF) is a major predictor of the new onset of rheumatoid arthritis (RA). In very early arthritis patients, higher titers…
Abstract Number: 2303 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Rheumatoid Factor-Positive Or Negative Subsets Of Anti-Citrullinated Peptide/Protein Antibody-Negative Rheumatoid Arthritis
Ryosuke Hiwa¹, Koichiro Ohmura¹, Noriyuki Yamakawa¹, Moritoshi Furu², Chikashi Terao³, Ran Nakashima¹, Yoshitaka Imura⁴, Naoichiro Yukawa⁵, Hajime Yoshifuji¹, Motomu Hashimoto⁶, Hiromu Ito², Takao Fujii² and Tsuneyo Mimori^1,2, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Center for Genomic Medicine, Kyoto University, Kyoto, Japan, ⁴Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁶The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Although anti-citrullinated peptide/protein antibody (ACPA) is a specific autoantibody for rheumatoid arthritis (RA), ~20% of RA are ACPA negative. It has been reported that…
Abstract Number: 2267 • 2013 ACR/ARHP Annual Meeting
The Diagnostic Accuracy Of Rheumatoid Factor Testing In Primary Care
Anne Miller¹, Alison L Nightingale², Cormac J Sammon³, Tim Holt⁴, Kamal R Mahtani⁵, Neil McHugh⁶, Corinne S de Vries³ and Raashid A. Luqmani^1,7, ¹Rheumatology, Nuffield Orthopaedic Centre, Oxford, United Kingdom, ²Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³Pharmacy & Pharmacology, University of Bath, Bath, United Kingdom, ⁴Primary Health Care Sciences, University of Oxford, Oxford, United Kingdom, ⁵Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom, ⁶Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁷Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom
Background/Purpose: Studies of the diagnostic utility of rheumatoid factor (RF) testing for rheumatoid arthritis (RA) conducted in early arthritis clinics in secondary care have reported…
Abstract Number: 1786 • 2013 ACR/ARHP Annual Meeting
91% Of Early RA Patients Are Positive For Serum 14-3-3η Or Its Auto-Antibodies
Walter P. Maksymowych¹, Dirkjan van Schaardenburg², Désirée van der Heijde³, Robert Landewé⁴, Gilles Boire⁵, Maarten Boers⁶, Vivian P. Bykerk⁷, Edward C. Keystone⁸, Katherine A. Siminovitch⁹, Mairead Murphy¹⁰ and Anthony Marotta¹¹, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Jan van Breemen Research Institute | Reade, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Int Med/Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁵Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁷Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁸Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Augurex Life Sciences Corp., North Vancouver, BC, Canada, ¹¹Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: Current serological markers such as RF and ACPA are useful for early diagnosis and perhaps for screening people at risk, but there remains a…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].